Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Loading...
Loading...
  • Seagen Inc SGEN announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. 
  • Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG RHHBY.
  • Data from this trial will form the basis of a planned supplemental marketing application to the FDA under the FDA's Accelerated Approval Program. 
  • Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence.
  • Merck & Co Inc MRK is commercializing Tukysa in regions outside the U.S., Canada, and Europe.
  • Results showed a 38.1% confirmed objective response rate (cORR).
  • The median duration of response (DoR) was 12.4 months. The combination of tucatinib and trastuzumab was generally well-tolerated. The most common adverse treatment-emergent events were diarrhea, fatigue, nausea, and infusion-related reaction, primarily low-grade.
  • Price Action: SGEN shares are up 0.82% at $140.79 during the market session on the last check Monday.
Posted In: BiotechNewsHealth CareGeneralBriefs
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...